Glaukos Corporation GKOS

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

• Zacks Investment Research 1 sept

  Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?

  Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.

  

• The Motley Fool 14 jul

  Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?

  Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising Epioxa product—suggest the sale does not indicate trouble for the company.

  

• The Motley Fool 8 jul

  Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

  Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.